基于比例失衡法的贝达喹啉不良事件信号挖掘与分析OA
Mining and analysis of adverse event signals for bedaquiline based on the disproportionality analysis
目的 对贝达喹啉药物不良事件(ADE)进行挖掘与分析,为贝达喹啉的临床合理用药提供依据.方法 收集美国食品药品监督管理局(FDA)不良事件上报系统(FAERS)中与贝达喹啉相关的ADE报告数据,采用比例失衡法中的报告比值比法和比例报告比值法对潜在的ADE信号进行挖掘,采用《国际医学用语词典》对筛选出的ADE进行首选术语标准化,并采用器官系统分类(SOC)法将ADE分类.结果 共检索到贝达喹啉相关ADE 1 445份,经筛选后得到129个阳性信号,累及18个SOC.在信号强度排名前20位的ADE中,有慢性肾盂肾炎、肺源性心脏病、耳毒性、心肺衰竭、前庭疾病等16个ADE未被贝达喹啉药品说明书记载;在发生频次排名前20位的ADE中,有贫血、周围神经病、低钾血症、呼吸衰竭、胃肠疾病等13个ADE未被贝达喹啉药品说明书记载.结论 挖掘到的贝达喹啉ADE与药品说明书中记载的不良反应具有一致性,但也存在较多新的ADE.在临床工作中应对使用贝达喹啉的患者进行耳及迷路类疾病、肾脏及泌尿系统疾病及各类神经系统疾病的监测,及时识别并及时处置贝达喹啉的不良反应,保障用药安全.
AIM To mine and analyze drug adverse events(ADE)associated with bedaquiline,providing a basis for rational clinical use of bedaquiline.METHODS ADE reports related to bedaquiline were collected from the FDA adverse event reporting system(FAERS)database.The reporting odds ratio(ROR)and proportional reporting ratio(PRR)methods in the disproportionality analysis were used to mine potential ADE signals.The selected ADE were standardized using the preferred term(PT)from the Medical Dictionary for Regulatory Activities(MedDRA),and classified according to the system organ class(SOC).RESULTS A total of 1 445 bedaquiline-related ADE reports were retrieved.After screening,129 positive signals were obtained,involving 18 SOCs.Among the top 20 ADE ranked by signal intensity,16 ADE were not mentioned in the drug label,including chronic pyelonephritis,cor pulmonale,ototoxicity,cardiopulmonary failure and vestibular disorder.Among the top 20 ADE ranked by frequency of occurrence,13 ADE were not mentioned in the drug label,including anemia,peripheral neuropathy,hypokalaemia,respiratory failure and gastrointestinal disorders.CONCLUSION The ADE of bedaquiline identified through data mining are partially consistent with those documented in the drug label,yet numerous novel ADE have been detected.In clinical practice,patients treated with bedaquiline should undergo regular monitoring for ear and labyrinth disorders,renal and urinary system disorders,and nervous system disorders,therefore,ADE can be identified and managed timely,ensuring medication safety.
张倩;张莉;董平
上海市公共卫生临床中心药剂科,上海 201508上海市公共卫生临床中心药剂科,上海 201508上海市公共卫生临床中心药剂科,上海 201508
医药卫生
贝达喹啉比例失衡法美国食品和药品监督管理局不良事件上报系统药品不良事件药物警戒信号挖掘
bedaquilinedisproportionality analysisFDA adverse event reporting systemdrug adverse eventpharmacovigilancedata mining
《中国临床药学杂志》 2026 (1)
70-75,6
评论